NEW YORK, Nov. 23, 2020 /PRNewswire/ --
Sharp Decline in Patient Throughput in Imaging Centers Due to COVID-19 Outbreak Induces a -6.3% Erosion in Demand for Radiopharmaceuticals
Read the full report: https://www.reportlinker.com/p01591554/?utm_source=PRN
The global market for Radiopharmaceuticals is expected to slump by -6.3% in the year 2020 and thereafter recover to reach US$9.9 billion by the year 2027, trailing a post COVID-19 CAGR of 9.4% over the analysis period 2020 through 2027. The healthcare supply chain is navigating unchartered, rough waters and struggling to maintain pace with rapidly increasing cases of COVID-19. The pandemic has devastated nearly all segments associated with the healthcare sector, such as medical devices, pharmaceuticals and essential supplies. Healthcare organizations globally are finding it extremely challenging to serve patients while ensuring safety of the medical staff due to marked shortage of supplies as a result of supply chain disruptions. The scenario is complicated by unprecedented scale of the pandemic along with few sourcing options and export restrictions. Amid the COVID-19 outbreak, most companies have reported some form of disruption in their supply chains owing to transportation restrictions. The crisis has also resulted in supply issues associated with radiopharmaceuticals, radioisotopes and kits for therapeutic and diagnostic applications. Nuclear medicine and personalized medicine are heavily reliant on the timely availability of radioisotopes. With air freight restrictions imposed, transport of Mo-99, Tc-99m and other radioisotopes remains impacted during COVID times. NTP Radioisotopes is currently operating at below normal capacity as a result of logistical challenges in South Africa.
While the US accounts for nearly half of the market, it relies on three suppliers of Molybdenum-99 and Technetium-99m. In addition, majority of African nations depend heavily on a single supplier of these radioisotopes that are used for cancer imaging. The COVID-19 outbreak has complicated the scenario owing to ongoing restrictions on flights that have severely disrupted global supply chains, prompting participants to ensure reliable radiopharmaceuticals supply for nuclear medicine. Participants are also facing issues in procuring cold kits for simplifying radiopharmaceutical production. These supply constraints along with shortage of qualified staff has made it challenging for countries to perform tasks such as labeling and quality assurance, hampering complex procedures. There are issues related to particular radiopharmaceuticals. While 18F-FDG is extensively used, non-FDG tracers remained in limited quantities across low-income nations owing to their extensive nature, regulatory restrictions and lack of cyclotron. In addition, various countries are unable to access therapeutic tracers including 123I, 123I-MIBG, and 131I-MIBG due to supply and cost issues. The scenario remains challenging for non-COVID-19 treatment solutions such as medical radioisotopes, which are used in diagnosis and treatment of cancer and certain health conditions by healthcare providers around the world. Every year, millions of patients are administered with radioisotopes for diagnosis and therapeutic purposes. With governments defining the medical radioisotope production facilities as 'essential', production operations continued during the COVID-19 pandemic period. Reactors engaged in production of radioisotopes remained operational in compliance with the relevant IAEA safety standards and in adherence to relevance measures to prevent the effects and spread of COVID-19 disease. Reactors based out of Argentina, Australia, Belgium, Czech Republic, Netherlands, Poland, Russia , USA, and South Africa, account for almost the entire world production of radioisotopes, and the radio compounds produced in these countries are transported worldwide mainly via aerial route.
In the post pandemic period, pent-up demand for cancer and other chronic diseases will push up demand for radioisotopes. The huge unmet needs and the ensuing massive opportunity for imaging technologies and services will benefit long-term growth of radiopharmaceuticals. Growth during this period will continue to benefit from the growing mainstream interest in nuclear medicine, and the development of new radionuclide's for cancer nuclear imaging and internal radiotherapy. A key trend of the pre-virus period that will emerge to spur gains is the shifting of healthcare from fee based systems to value based systems and the resulting new commercial value placed on hybrid molecular imaging techniques which utilize radiopharmaceuticals for accurate and early disease diagnosis. Development of new and innovative radiopharmaceuticals has and will continue to spur the use of PET/CT and SPECT/CT imaging platforms across new clinical areas including cardiology, neurology, orthopedics, pulmonology and oncology. The epidemic spread of cancer will fuel interest in non-invasive tumor receptor imaging thereby pushing up the significance of molecular imaging for its ability to enable better understanding of tumor biology so as to develop more personalized and targeted treatment regimes. Other growth drivers will include growing incidence of cardiovascular diseases and new launch of cardiac radiopharmaceuticals such as flurpiridaz f-18 and ammonia n-13 in the field of cardiovascular disease imaging; expected developments in non-reactor based production of tc-99m in a bid to overcome production challenges of Tc-99m; growing population and healthcare burden; pressing need for effective healthcare solutions; government policy led focus on healthcare infrastructure development; and concerted efforts taken to promote nuclear medicine in emerging Asian economies grappling with the economic challenges of providing affordable healthcare.
Competitors identified in this market include, among others,
- Actinium Pharmaceuticals Inc.
- Alliance Medical
- Alseres Pharmaceuticals Inc.
- Avid Radiopharmaceuticals
- Bayer HealthCare, Radiology Division
- Bracco Diagnostics Inc.
- Cardinal Health, Inc.
- GE Healthcare
- Immunomedics, Inc.
- Ion Beam Applications SA
- Jubilant Pharma
- Lantheus Medical Imaging Inc.
- Medi-Radiopharma Ltd.
- Nordion, Inc.
- Peregrine Pharmaceuticals, Inc.
- PETNET Solutions Inc.
- Positron Corporation
- Triad Isotopes Inc.
Read the full report: https://www.reportlinker.com/p01591554/?utm_source=PRN
I. INTRODUCTION, METHODOLOGY & REPORT SCOPE I-1
II. EXECUTIVE SUMMARY II-1
1. MARKET OVERVIEW II-1
Impact of Covid-19 and a Looming Global Recession II-1
COVID-19-Led Disruptions Exhaust Radiopharmaceuticals Supply to
Hinder Nuclear Medicine Procedures in Most Countries II-2
Exhibit 1: Imaging Screening Volume % Change 1H 2019 Vs 1H 2020
in U.S Hospitals II-3
Distribution Bottlenecks amid COVID-19 Crisis Leave Hospitals
Struggling with Seamless Supply of Medical Radioisotopes II-3
Nuclear Medicine Services Limp Back to Normality after Easing
of COVID-19 Restrictions II-4
COVID-19 Presents Generational Opportunity II-5
Radiopharmaceuticals: A Prelude II-5
Mechanism of Action II-6
Global Supply Shortages Continue to Challenge Market Growth II-6
Exhibit 2: A Glimpse at Mo-99 Processors Worldwide II-8
Exhibit 3: Nuclear Research Reactor Irradiators Worldwide: A
Snapshot II-9
Outlook II-9
Key Market Drivers II-10
Market Restraints II-11
Recognition of Intrinsic Cost Benefits: Critical to Market
Acceptance II-13
Classification of Radiopharmaceuticals II-13
Diagnostic Radiopharmaceuticals: The Dominant Segment II-13
Key Drivers II-14
Positron Emission Tomography (PET) II-15
Major PET Isotopes and their Applications II-16
Single Photon Emission Computed Tomography (SPECT) II-16
Major Isotopes and their Diagnostic Applications II-17
Therapeutic Radiopharmaceuticals II-18
Select Isotopes and their Therapeutic Applications II-18
Key Drivers II-18
Competitive Landscape II-19
Exhibit 4: Radiopharmaceuticals Competitor Market Share
Scenario Worldwide (in %): 2019 II-19
Recent Industry Activity II-20
World Brands II-23
2. FOCUS ON SELECT PLAYERS II-24
3. MARKET TRENDS & DRIVERS II-26
Emergence of Radiotheranostics: Dual-Functioning
Radiopharmaceuticals II-26
Changing Role of Radiopharmaceuticals in Diagnostic and
Therapeutic Applications II-26
Advent of New Radiopharmaceuticals Widen Scope II-27
Select New Products II-28
Industry Focus Gears up for Innovative Radiopharmaceuticals
with Therapeutic Benefits II-28
Select Commercially Available Therapeutic Radiopharmaceuticals II-29
PET Eclipses SPECT in Cardiovascular Imaging II-30
Exhibit 5: Worldwide Installed Base of Nuclear Imaging
Equipment by Modality, PET Vs SPECT: 2019 II-30
Cardiac Amyloidosis Visualization: A Potential Application for PET II-31
Innovative Radiopharmaceuticals to Boost Cardiac Applications II-31
Exhibit 6: Fatalities by Heart Conditions - Estimated
Percentage Breakdown for Cardiovascular Disease, Ischemic
Heart Disease, Stroke, and Others II-32
Application of PET in Drug Development to Expand Opportunities II-32
Intra-operative Lymphatic Mapping (ILM): Creates New
Opportunities for Radiopharmaceuticals in Cancer Detection II-33
Personalized Medicine Drives Nuclear Medicine II-34
Exhibit 7: Drug Ineffectiveness for Select Therapeutic
Categories as a Percentage of Patient Population II-35
Exhibit 8: Global Personalized Medicine Market: Revenues in US$
Million for the Years 2019 and 2024 II-36
Rise in Incidence of Neurological Disorders to Drive Growth II-36
Rising Cancer Incidence Worldwide Spurs Demand II-37
Exhibit 9: Global Cancer Incidence: Number of New Cancer Cases
in Million for the Years 2018, 2020, 2025, 2030, 2035 and 2040 II-38
Exhibit 10: Global Number of New Cancer Cases and Cancer-
related Deaths by Cancer Site for 2018 II-39
Exhibit 11: Number of New Cancer Cases and Deaths (in Million)
by Region for 2018 II-40
Ageing Population: A Vital Demography II-40
Exhibit 12: Global Aging Population: Population of 65+
Individuals (in Thousands) by Region for 2019 and 2030 II-41
Exhibit 13: Global Cancer Deaths by Age Group (in %) for 2019 II-42
Rise in Healthcare Expenditure to Drive Growth II-42
Exhibit 14: Elderly Healthcare Expenditure as a % of GDP II-44
Exhibit 15: World Healthcare Expenditure (In US$ Billion) for
the Years 2017-2023 II-44
Relevant Aspects of Radiopharmaceutical Production II-45
Regulatory Regime Governing Production and Use of
Radiopharmaceuticals II-45
4. GLOBAL MARKET PERSPECTIVE II-47
Table 1: World Current & Future Analysis for
Radiopharmaceuticals by Geographic Region - USA, Canada, Japan,
China, Europe, Asia-Pacific, Latin America, Middle East and
Africa Markets - Independent Analysis of Annual Sales in US$
Thousand for Years 2020 through 2027 II-47
Table 2: World Historic Review for Radiopharmaceuticals by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2016 through 2019 II-48
Table 3: World 11-Year Perspective for Radiopharmaceuticals by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa Markets for Years 2016, 2020 & 2027 II-49
Table 4: World Current & Future Analysis for SPECT
Radioisotopes by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets - Independent Analysis of Annual Sales in US$ Thousand
for Years 2020 through 2027 II-50
Table 5: World Historic Review for SPECT Radioisotopes by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2016 through 2019 II-51
Table 6: World 11-Year Perspective for SPECT Radioisotopes by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2016, 2020 & 2027 II-52
Table 7: World Current & Future Analysis for PET Radioisotopes
by Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2020 through 2027 II-53
Table 8: World Historic Review for PET Radioisotopes by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2016 through 2019 II-54
Table 9: World 11-Year Perspective for PET Radioisotopes by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2016, 2020 & 2027 II-55
Table 10: World Current & Future Analysis for Beta Emitters by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2020 through 2027 II-56
Table 11: World Historic Review for Beta Emitters by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin
America, Middle East and Africa Markets - Independent Analysis
of Annual Sales in US$ Thousand for Years 2016 through 2019 II-57
Table 12: World 11-Year Perspective for Beta Emitters by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2016, 2020 & 2027 II-58
Table 13: World Current & Future Analysis for Alpha Emitters by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2020 through 2027 II-59
Table 14: World Historic Review for Alpha Emitters by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2016 through 2019 II-60
Table 15: World 11-Year Perspective for Alpha Emitters by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2016, 2020 & 2027 II-61
Table 16: World Current & Future Analysis for Other Product
Types by Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2020 through 2027 II-62
Table 17: World Historic Review for Other Product Types by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2016 through 2019 II-63
Table 18: World 11-Year Perspective for Other Product Types by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2016, 2020 & 2027 II-64
Table 19: World Current & Future Analysis for Oncology by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2020 through 2027 II-65
Table 20: World Historic Review for Oncology by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin
America, Middle East and Africa Markets - Independent Analysis
of Annual Sales in US$ Thousand for Years 2016 through 2019 II-66
Table 21: World 11-Year Perspective for Oncology by Geographic
Region - Percentage Breakdown of Value Sales for USA, Canada,
Japan, China, Europe, Asia-Pacific, Latin America, Middle East
and Africa for Years 2016, 2020 & 2027 II-67
Table 22: World Current & Future Analysis for Cardiology by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2020 through 2027 II-68
Table 23: World Historic Review for Cardiology by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin
America, Middle East and Africa Markets - Independent Analysis
of Annual Sales in US$ Thousand for Years 2016 through 2019 II-69
Table 24: World 11-Year Perspective for Cardiology by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2016, 2020 & 2027 II-70
Table 25: World Current & Future Analysis for Neurology by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2020 through 2027 II-71
Table 26: World Historic Review for Neurology by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin
America, Middle East and Africa Markets - Independent Analysis
of Annual Sales in US$ Thousand for Years 2016 through 2019 II-72
Table 27: World 11-Year Perspective for Neurology by Geographic
Region - Percentage Breakdown of Value Sales for USA, Canada,
Japan, China, Europe, Asia-Pacific, Latin America, Middle East
and Africa for Years 2016, 2020 & 2027 II-73
Table 28: World Current & Future Analysis for Other
Applications by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets - Independent Analysis of Annual Sales in US$ Thousand
for Years 2020 through 2027 II-74
Table 29: World Historic Review for Other Applications by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2016 through 2019 II-75
Table 30: World 11-Year Perspective for Other Applications by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2016, 2020 & 2027 II-76
Table 31: World Current & Future Analysis for Hospitals &
Diagnostic Centers by Geographic Region - USA, Canada, Japan,
China, Europe, Asia-Pacific, Latin America, Middle East and
Africa Markets - Independent Analysis of Annual Sales in US$
Thousand for Years 2020 through 2027 II-77
Table 32: World Historic Review for Hospitals & Diagnostic
Centers by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets - Independent Analysis of Annual Sales in US$ Thousand
for Years 2016 through 2019 II-78
Table 33: World 11-Year Perspective for Hospitals & Diagnostic
Centers by Geographic Region - Percentage Breakdown of Value
Sales for USA, Canada, Japan, China, Europe, Asia-Pacific,
Latin America, Middle East and Africa for Years 2016, 2020 &
2027 II-79
Table 34: World Current & Future Analysis for Ambulatory
Surgical Centers by Geographic Region - USA, Canada, Japan,
China, Europe, Asia-Pacific, Latin America, Middle East and
Africa Markets - Independent Analysis of Annual Sales in US$
Thousand for Years 2020 through 2027 II-80
Table 35: World Historic Review for Ambulatory Surgical Centers
by Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2016 through 2019 II-81
Table 36: World 11-Year Perspective for Ambulatory Surgical
Centers by Geographic Region - Percentage Breakdown of Value
Sales for USA, Canada, Japan, China, Europe, Asia-Pacific,
Latin America, Middle East and Africa for Years 2016, 2020 &
2027 II-82
Table 37: World Current & Future Analysis for Other End-Uses by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2020 through 2027 II-83
Table 38: World Historic Review for Other End-Uses by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2016 through 2019 II-84
Table 39: World 11-Year Perspective for Other End-Uses by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2016, 2020 & 2027 II-85
III. MARKET ANALYSIS III-1
GEOGRAPHIC MARKET ANALYSIS III-1
UNITED STATES III-1
Market Overview III-1
Diagnostic Applications Stimulate Future Growth III-1
Demographic Changes Offer Growth Opportunities III-2
Exhibit 16: US Elderly Population: Expected Growth Rates Over
the Years 2005-2025 III-2
Rising Incidence of Cancer: A Major Growth Driver III-3
Exhibit 17: Leading Sites of New Cancer Cases in Males: 2020 III-3
Exhibit 18: Leading Sites of New Cancer Cases in Females: 2020 III-4
Cardiovascular Imaging to Lead Volume Growth III-4
Radiopharmaceuticals Usage Strengthens in PET Imaging III-5
Radioisotope/Radiopharmaceuticals Supply Scenario III-6
Passing of Medicare Diagnostic Radiopharmaceutical Payment
Equity Act III-7
Market Analytics III-8
Table 40: USA Current & Future Analysis for
Radiopharmaceuticals by Product Type - SPECT Radioisotopes, PET
Radioisotopes, Beta Emitters, Alpha Emitters and Other Product
Types - Independent Analysis of Annual Sales in US$ Thousand
for the Years 2020 through 2027 III-8
Table 41: USA Historic Review for Radiopharmaceuticals by
Product Type - SPECT Radioisotopes, PET Radioisotopes, Beta
Emitters, Alpha Emitters and Other Product Types Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2016 through 2019 III-9
Table 42: USA 11-Year Perspective for Radiopharmaceuticals by
Product Type - Percentage Breakdown of Value Sales for SPECT
Radioisotopes, PET Radioisotopes, Beta Emitters, Alpha Emitters
and Other Product Types for the Years 2016, 2020 & 2027 III-10
Table 43: USA Current & Future Analysis for
Radiopharmaceuticals by Application - Oncology, Cardiology,
Neurology and Other Applications - Independent Analysis of
Annual Sales in US$ Thousand for the Years 2020 through 2027 III-11
Table 44: USA Historic Review for Radiopharmaceuticals by
Application - Oncology, Cardiology, Neurology and Other
Applications Markets - Independent Analysis of Annual Sales in
US$ Thousand for Years 2016 through 2019 III-12
Table 45: USA 11-Year Perspective for Radiopharmaceuticals by
Application - Percentage Breakdown of Value Sales for Oncology,
Cardiology, Neurology and Other Applications for the Years
2016, 2020 & 2027 III-13
Table 46: USA Current & Future Analysis for
Radiopharmaceuticals by End-Use - Hospitals & Diagnostic
Centers, Ambulatory Surgical Centers and Other End-Uses -
Independent Analysis of Annual Sales in US$ Thousand for the
Years 2020 through 2027 III-14
Table 47: USA Historic Review for Radiopharmaceuticals by
End-Use - Hospitals & Diagnostic Centers, Ambulatory Surgical
Centers and Other End-Uses Markets - Independent Analysis of
Annual Sales in US$ Thousand for Years 2016 through 2019 III-15
Table 48: USA 11-Year Perspective for Radiopharmaceuticals by
End-Use - Percentage Breakdown of Value Sales for Hospitals &
Diagnostic Centers, Ambulatory Surgical Centers and Other
End-Uses for the Years 2016, 2020 & 2027 III-16
CANADA III-17
Market Overview III-17
Efforts on to Address Mo-99 Supply Shortage III-17
Market Analytics III-18
Table 49: Canada Current & Future Analysis for
Radiopharmaceuticals by Product Type - SPECT Radioisotopes, PET
Radioisotopes, Beta Emitters, Alpha Emitters and Other Product
Types - Independent Analysis of Annual Sales in US$ Thousand
for the Years 2020 through 2027 III-18
Table 50: Canada Historic Review for Radiopharmaceuticals by
Product Type - SPECT Radioisotopes, PET Radioisotopes, Beta
Emitters, Alpha Emitters and Other Product Types Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2016 through 2019 III-19
Table 51: Canada 11-Year Perspective for Radiopharmaceuticals
by Product Type - Percentage Breakdown of Value Sales for SPECT
Radioisotopes, PET Radioisotopes, Beta Emitters, Alpha Emitters
and Other Product Types for the Years 2016, 2020 & 2027 III-20
Table 52: Canada Current & Future Analysis for
Radiopharmaceuticals by Application - Oncology, Cardiology,
Neurology and Other Applications - Independent Analysis of
Annual Sales in US$ Thousand for the Years 2020 through 2027 III-21
Table 53: Canada Historic Review for Radiopharmaceuticals by
Application - Oncology, Cardiology, Neurology and Other
Applications Markets - Independent Analysis of Annual Sales in
US$ Thousand for Years 2016 through 2019 III-22
Table 54: Canada 11-Year Perspective for Radiopharmaceuticals
by Application - Percentage Breakdown of Value Sales for
Oncology, Cardiology, Neurology and Other Applications for the
Years 2016, 2020 & 2027 III-23
Table 55: Canada Current & Future Analysis for
Radiopharmaceuticals by End-Use - Hospitals & Diagnostic
Centers, Ambulatory Surgical Centers and Other End-Uses -
Independent Analysis of Annual Sales in US$ Thousand for the
Years 2020 through 2027 III-24
Table 56: Canada Historic Review for Radiopharmaceuticals by
End-Use - Hospitals & Diagnostic Centers, Ambulatory Surgical
Centers and Other End-Uses Markets - Independent Analysis of
Annual Sales in US$ Thousand for Years 2016 through 2019 III-25
Table 57: Canada 11-Year Perspective for Radiopharmaceuticals
by End-Use - Percentage Breakdown of Value Sales for Hospitals
& Diagnostic Centers, Ambulatory Surgical Centers and Other
End-Uses for the Years 2016, 2020 & 2027 III-26
JAPAN III-27
Market Overview III-27
Market Analytics III-28
Table 58: Japan Current & Future Analysis for
Radiopharmaceuticals by Product Type - SPECT Radioisotopes, PET
Radioisotopes, Beta Emitters, Alpha Emitters and Other Product
Types - Independent Analysis of Annual Sales in US$ Thousand
for the Years 2020 through 2027 III-28
Table 59: Japan Historic Review for Radiopharmaceuticals by
Product Type - SPECT Radioisotopes, PET Radioisotopes, Beta
Emitters, Alpha Emitters and Other Product Types Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2016 through 2019 III-29
Table 60: Japan 11-Year Perspective for Radiopharmaceuticals by
Product Type - Percentage Breakdown of Value Sales for SPECT
Radioisotopes, PET Radioisotopes, Beta Emitters, Alpha Emitters
and Other Product Types for the Years 2016, 2020 & 2027 III-30
Table 61: Japan Current & Future Analysis for
Radiopharmaceuticals by Application - Oncology, Cardiology,
Neurology and Other Applications - Independent Analysis of
Annual Sales in US$ Thousand for the Years 2020 through 2027 III-31
Table 62: Japan Historic Review for Radiopharmaceuticals by
Application - Oncology, Cardiology, Neurology and Other
Applications Markets - Independent Analysis of Annual Sales in
US$ Thousand for Years 2016 through 2019 III-32
Table 63: Japan 11-Year Perspective for Radiopharmaceuticals by
Application - Percentage Breakdown of Value Sales for Oncology,
Cardiology, Neurology and Other Applications for the Years
2016, 2020 & 2027 III-33
Table 64: Japan Current & Future Analysis for
Radiopharmaceuticals by End-Use - Hospitals & Diagnostic
Centers, Ambulatory Surgical Centers and Other End-Uses -
Independent Analysis of Annual Sales in US$ Thousand for the
Years 2020 through 2027 III-34
Table 65: Japan Historic Review for Radiopharmaceuticals by
End-Use - Hospitals & Diagnostic Centers, Ambulatory Surgical
Centers and Other End-Uses Markets - Independent Analysis of
Annual Sales in US$ Thousand for Years 2016 through 2019 III-35
Table 66: Japan 11-Year Perspective for Radiopharmaceuticals by
End-Use - Percentage Breakdown of Value Sales for Hospitals &
Diagnostic Centers, Ambulatory Surgical Centers and Other
End-Uses for the Years 2016, 2020 & 2027 III-36
CHINA III-37
Market Overview III-37
Market Analytics III-37
Table 67: China Current & Future Analysis for
Radiopharmaceuticals by Product Type - SPECT Radioisotopes, PET
Radioisotopes, Beta Emitters, Alpha Emitters and Other Product
Types - Independent Analysis of Annual Sales in US$ Thousand
for the Years 2020 through 2027 III-37
Table 68: China Historic Review for Radiopharmaceuticals by
Product Type - SPECT Radioisotopes, PET Radioisotopes, Beta
Emitters, Alpha Emitters and Other Product Types Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2016 through 2019 III-38
Table 69: China 11-Year Perspective for Radiopharmaceuticals by
Product Type - Percentage Breakdown of Value Sales for SPECT
Radioisotopes, PET Radioisotopes, Beta Emitters, Alpha Emitters
and Other Product Types for the Years 2016, 2020 & 2027 III-39
Table 70: China Current & Future Analysis for
Radiopharmaceuticals by Application - Oncology, Cardiology,
Neurology and Other Applications - Independent Analysis of
Annual Sales in US$ Thousand for the Years 2020 through 2027 III-40
Table 71: China Historic Review for Radiopharmaceuticals by
Application - Oncology, Cardiology, Neurology and Other
Applications Markets - Independent Analysis of Annual Sales in
US$ Thousand for Years 2016 through 2019 III-41
Table 72: China 11-Year Perspective for Radiopharmaceuticals by
Application - Percentage Breakdown of Value Sales for Oncology,
Cardiology, Neurology and Other Applications for the Years
2016, 2020 & 2027 III-42
Table 73: China Current & Future Analysis for
Radiopharmaceuticals by End-Use - Hospitals & Diagnostic
Centers, Ambulatory Surgical Centers and Other End-Uses -
Independent Analysis of Annual Sales in US$ Thousand for the
Years 2020 through 2027 III-43
Table 74: China Historic Review for Radiopharmaceuticals by
End-Use - Hospitals & Diagnostic Centers, Ambulatory Surgical
Centers and Other End-Uses Markets - Independent Analysis of
Annual Sales in US$ Thousand for Years 2016 through 2019 III-44
Table 75: China 11-Year Perspective for Radiopharmaceuticals by
End-Use - Percentage Breakdown of Value Sales for Hospitals &
Diagnostic Centers, Ambulatory Surgical Centers and Other
End-Uses for the Years 2016, 2020 & 2027 III-45
EUROPE III-46
Market Overview III-46
Market Analytics III-47
Table 76: Europe Current & Future Analysis for
Radiopharmaceuticals by Geographic Region - France, Germany,
Italy, UK, Spain, Russia and Rest of Europe Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2020 through 2027 III-47
Table 77: Europe Historic Review for Radiopharmaceuticals by
Geographic Region - France, Germany, Italy, UK, Spain, Russia
and Rest of Europe Markets - Independent Analysis of Annual
Sales in US$ Thousand for Years 2016 through 2019 III-48
Table 78: Europe 11-Year Perspective for Radiopharmaceuticals
by Geographic Region - Percentage Breakdown of Value Sales for
France, Germany, Italy, UK, Spain, Russia and Rest of Europe
Markets for Years 2016, 2020 & 2027 III-49
Table 79: Europe Current & Future Analysis for
Radiopharmaceuticals by Product Type - SPECT Radioisotopes, PET
Radioisotopes, Beta Emitters, Alpha Emitters and Other Product
Types - Independent Analysis of Annual Sales in US$ Thousand
for the Years 2020 through 2027 III-50
Table 80: Europe Historic Review for Radiopharmaceuticals by
Product Type - SPECT Radioisotopes, PET Radioisotopes, Beta
Emitters, Alpha Emitters and Other Product Types Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2016 through 2019 III-51
Table 81: Europe 11-Year Perspective for Radiopharmaceuticals
by Product Type - Percentage Breakdown of Value Sales for SPECT
Radioisotopes, PET Radioisotopes, Beta Emitters, Alpha Emitters
and Other Product Types for the Years 2016, 2020 & 2027 III-52
Table 82: Europe Current & Future Analysis for
Radiopharmaceuticals by Application - Oncology, Cardiology,
Neurology and Other Applications - Independent Analysis of
Annual Sales in US$ Thousand for the Years 2020 through 2027 III-53
Table 83: Europe Historic Review for Radiopharmaceuticals by
Application - Oncology, Cardiology, Neurology and Other
Applications Markets - Independent Analysis of Annual Sales in
US$ Thousand for Years 2016 through 2019 III-54
Please contact our Customer Support Center to get the complete Table of Contents
Read the full report: https://www.reportlinker.com/p01591554/?utm_source=PRN
About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.
Contact Clare: [email protected]
US: (339)-368-6001
Intl: +1 339-368-6001
SOURCE Reportlinker
Share this article